Free from Publisher

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

G Meyer, B Besse, H Doubre… - European …, 2018 - Eur Respiratory Soc
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …
被引用次数：56 相关文章

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

G Meyer, B Besse, H Doubre… - European Respiratory …, 2018 - hal.science
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

G Meyer, B Besse, H Doubre… - The European …, 2018 - europepmc.org
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

G Meyer, B Besse, H Doubre… - The European …, 2018 - pubmed.ncbi.nlm.nih.gov
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …

Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial

G Meyer, B Besse, H Doubre… - European …, 2018 - Eur Respiratory Soc
Background: The antitumor and antimetastatic properties of heparins have not been tested
in patients with early-stage cancer. Whether adjuvant low molecular weight heparin (LMWH) …

Anti-tumour effect of low molecular weight heparin in localised lung cancer: A phase III clinical trial

G Meyer, B Besse, H Doubre… - European …, 2018 - research.monash.edu
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients
with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin …